HRs for type 2 diabetes in prostate cancer by use of ADT
| HR | 95% CI | aHR* | 95% CI | |
| ADT-free cohort | ref. | – | ref. | – |
| ADT users | 1.49 | 1.34 to 1.66 | 1.47 | 1.32 to 1.64 |
| GnRH agonists users | 1.53 | 1.38 to 1.71 | 1.51 | 1.35 to 1.69 |
| Antiandrogen users | 1.02 | 0.75 to 1.40 | 1.02 | 0.74 to 1.39 |
*Adjusted for age and stage.
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone.